Despite successfully lowering Lp(a) levels, pelacarsen failed to reduce major adverse cardiovascular events in the phase 3 Lp(a)HORIZON trial.

“This is the first-ever optical use of a collagen scaffold containing two types of stem cells and has proved effective for a previously untreatable progressive condition leading to sight loss,” ...

Preoperative iron is associated with an improvement in number of days alive and at home in the first 90 days after surgery.

Illicit-source fentanyl exposure is linked to a significantly higher risk of opioid-related harmful outcomes than medical-source exposure, according to a study ...

Adverse feature count does not significantly modify the overall survival or metastasis-free survival benefits of hormone therapy ...

HealthDay News — Updated recommendations are presented for adult stroke rehabilitation and recovery in a guideline issued by the American Heart Association and American Stroke Association and ...

FDA approves updated 2026-2027 COVID-19 vaccine formulations targeting the XFG variant for older adults and high-risk ...

Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant ...

HealthDay News — Paternal exposure to valproate during sperm development is not associated with neurodevelopmental disorders (NDDs) in offspring, according to a study published online August 19 in ...

HealthDay News — Baseline cortical atrophy measured within the early-onset Alzheimer disease (EOAD) signature, a set of predominantly parietotemporal regions showing greater atrophy in EOAD than in ...

Interim Phase 1b/2a trial data support the MKK4 inhibitor's potential to protect hepatocytes and accelerate liver regeneration following surgical resection.

Phase 3 RASolute 302 data show daraxonrasib significantly extended overall and progression free survival compared with ...